Drug Target Review

AUGUST 6, 2024

Liver Fibrosis : Targeted therapies using ADCs could help reduce liver fibrosis and prevent the progression to cirrhosis. How do companies prioritise their R&D investment between oncology and other therapeutic areas for ADCs? How do companies prioritise their R&D investment between oncology and other therapeutic areas for ADCs?

Therapies 119

Therapies Pharmaceutical Companies Disease Treatment 119

The Pharma Data

JUNE 25, 2025

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.

RNA 52

RNA Clinical Trials Disease Small Molecule 52

Drug Channels

MARCH 22, 2024

Adam discusses how patients seeking to access specialty therapies can benefit from a digital intake approach. He then explains three ways that specialty pharmaceutical companies can use digital intake strategies to speed patient enrollment. Today’s guest post comes from Adam Stotts, SVP of Customer Success at AssistRx.

Pharmaceutical Companies 98

Pharmaceutical Companies Therapies Pharmaceuticals Drugs 98

The Pharma Data

JUNE 24, 2025

Oncology remains a core priority, reflecting the rising global burden of cancer and the need for more effective, targeted therapies. The goal is to transform laboratory discoveries into clinically relevant therapies that can reach patients faster and more efficiently.

Pharma R&D 40

Pharma R&D Pharmaceutical Companies Pharmaceuticals Science 40

DrugBank

MARCH 7, 2024

Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options. Key Players and Challenges For pharmaceutical giants like Novo Nordisk and Eli Lilly, 2024 presents both opportunities and challenges.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Clinical Trials Therapies 98

Drug Target Review

JULY 3, 2025

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials. A hindering factor is that knowledge about failed assets and why they failed is often unpublished and limited.

Drug Development 64

Drug Development Drugs Animal Testing Engineering 64

The Pharma Data

JUNE 18, 2025

The investigational ADC is built using Daiichi Sankyo’s proprietary DXd technology and represents one of the newest generation of targeted cancer therapies. It will enroll patients with mCRPC who have experienced disease progression during or after ARPI therapy.

Trials 40

Trials Therapies Clinical Trials Treatment 40

Drug Patent Watch

DECEMBER 9, 2024

This includes: Preclinical studies Clinical trials Regulatory approval Manufacturing and marketing Throughout this process, pharmaceutical companies seek to protect their investments through patents.

Drugs 94

Drugs Drug Development Pharmaceuticals Production 94

The Pharma Data

JULY 3, 2025

NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies, and other therapeutic areas, has announced the commercial launch of its first biosimilar drug, NIOPEG® , in Canada.

Marketing 52

Marketing Biosimilars Pharmaceutical Companies Pharmaceuticals 52

DrugBank

OCTOBER 4, 2024

Emerging Markets Emerging markets, particularly in Asia and Latin America, have become increasingly attractive destinations for pharmaceutical M&A activity. The growing middle class and government initiatives to improve access to medicines have created an ecosystem for pharmaceutical companies seeking growth opportunities.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

Drug Target Review

JUNE 2, 2025

Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments.

Small Molecule 52

Small Molecule Engineering Therapies Drugs 52

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Target Review

JANUARY 8, 2024

Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. a commercial stage pharmaceutical company. acquired by Teva Pharmaceuticals in 2014.

Science 145

Science Disease FDA Approval Pharmaceutical Companies 145

DrugBank

MARCH 15, 2024

Eli Lilly's Triumph: Pioneering Solutions in Weight Management Eli Lilly's remarkable achievement with its drug Mounjaro (tirzepatide) in the fourth quarter of 2023 has sent ripples of excitement through the pharmaceutical industry. This has caused a great deal of hesitation from pharmaceutical companies in the past.

Pharmaceutical Companies 97

Pharmaceutical Companies Pharmaceuticals Treatment Clinical Trials 97

Alta Sciences

JULY 3, 2025

It was the perfect venue for meaningful conversations with pharmaceutical companies, fellow CROs, and academic experts, all eager to explore the latest breakthroughs in drug development. BIG IDEAS AND BRIGHT CONVERSATIONS ABOUT DRUG DEVELOPMENT The CPHI Innovation Theater was buzzing with energy—and Altasciences was right in the mix.

Small Molecule 52

Small Molecule Drug Development Pharmaceuticals Science 52

The Pharma Data

JUNE 6, 2025

The Strategic Role of CSOs in a Changing Pharmaceutical Landscape Pharmaceutical contract sales outsourcing is no longer viewed as a temporary or stop-gap measure. Equally important is regulatory compliance. Today’s CSOs are expected to adhere to frameworks like HIPAA , GDPR , the Sunshine Act , and regional promotional codes.

Pharmaceutical Companies 40

Pharmaceutical Companies Compliance Pharmaceuticals International 40

Drug Target Review

DECEMBER 11, 2024

This approach not only boosts our clients’ ability to achieve high accuracy and meet regulatory requirements but also supports the seamless transition of innovative therapies from the lab to the clinic with confidence.

International 52

International Laboratories Drugs Pharmacokinetics 52

The Pharma Data

MAY 27, 2022

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah ® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy.

FDA Approval 52

FDA Approval Therapies FDA Treatment 52

The Pharma Data

MARCH 29, 2022

Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) today announce Boehringer Ingelheim’s selection of Veeva Development Cloud to drive end-to-end processes and seamless information sharing enterprise wide for greater speed in the delivery of innovative therapies. About Boehringer Ingelheim.

Therapies 52

Therapies Clinical Development Pharmaceutical Companies Research 52

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Clinical Research 98

Clinical Research Pharmaceutical Companies Clinical Development Drug Development 98

Drug Target Review

MARCH 3, 2025

In this interview, Professor Schwamborn discusses his research, the promise of brain organoids, and his vision for the future of stem cell-based therapies. However, promising pilot data from ongoing collaborations with pharmaceutical companies suggest that brain organoids are set to become a valuable tool in preclinical research.

Disease 52

Disease Treatment Cell Biology Therapies 52

Conversations in Drug Development Trends

DECEMBER 7, 2023

Moreover, these delays impact getting potentially lifesaving therapies to patients in need. We are acutely aware that turnover in key project team personnel can lengthen project timelines and inflate clinical trial costs.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

Drug Target Review

OCTOBER 1, 2024

Following clinical practice, I transitioned to the world of pharmaceutical companies which also had its challenges as I had to learn everything from scratch and use my experience and knowledge differently. That paper, of which I was in the authorship, remains a current point of reference for that therapy usage.

Doctors 97

Doctors Therapies Science Pharma Companies 97

The Pharma Data

OCTOBER 21, 2020

In the midst of the global pandemic, the analysis found no antiretroviral therapy interruptions across the entirety of the ongoing clinical development programme for long-acting cabotegravir and rilpivirine. Of those participants who transitioned back to injectables, the median duration of oral therapy was 51 days.

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

LifeSciVC

OCTOBER 13, 2022

This summer, approvals on both sides of the Atlantic – for beta thalassemia and cerebral adrenoleukodystrophy in the United States and for severe hemophilia A and aromatic L-amino acid carboxylase deficiency in Europe – show that regulators are likely open to green-lighting a range of emerging gene therapies.

Therapies 40

Therapies Disease Marketing Treatment 40

The Pharma Data

JANUARY 5, 2021

The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. This will enable additional investment from venture capital firms and/or pharmaceutical companies on the path to approval. FREIBURG, Germany , Jan.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Regulations Drugs 52

Eye on FDA

NOVEMBER 9, 2023

In fact, looking back to enforcement beyond this year through March of 2022, one can see that the last 7 letters issued by OPDP to pharmaceutical companies about promotional communications all involved a tie between a particular efficacy claim and the data from which it was derived, or where an efficacy claim appeared unsupported by data.

FDA 88

FDA Pharmaceutical Companies Production Pharmaceuticals 88

Fierce BioTech

DECEMBER 27, 2023

As a result of these challenges, there is a growing need for companies to develop strategies outside of the traditional distribution channels that provide direct-to-patient access paths to medication. This webinar will explore innovative Direct-to-Patient cash solutions as a way to improve accessibility, convenience, and patient outcomes.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmacy Therapies Pharmaceuticals 52

Conversations in Drug Development Trends

APRIL 4, 2024

The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies. Understanding and implementing the ICH M10 guidelines is not just a regulatory requirement; it’s a step towards more efficient and effective pharmaceutical research.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

DrugBank

JANUARY 15, 2025

Introduction Orphan drugs, specifically developed to treat rare diseases, represent a unique and challenging pharmaceutical industry segment. Characterized by small patient populations, high development costs, and complex regulatory pathways, these therapies navigate a landscape distinct from blockbuster drugs targeting common diseases.

Drugs 52

Drugs Drug Development Clinical Trials Therapies 52

Crown Bioscience

MAY 4, 2021

Crown Bioscience Director Mike Batey takes a closer look at pediatric cancer and how recent regulatory changes and additional research focus may deliver new therapies for kids. Unfortunately, children have limited access to novel therapies, and new drugs for adults are often only tested in children many years following approval.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

DrugBank

JUNE 27, 2024

Drug repurposing’s potential to target undruggable molecules is showing huge promise for its ability to accelerate the development of new therapies and improve patient outcomes. Repurposing drug combinations expands the possibilities beyond single-drug therapies.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

Agency IQ

FEBRUARY 12, 2024

BY RACHEL COE, MSC | FEB 7, 2024 10:21 PM CST The Bespoke Gene Therapy Consortium A collaborative effort, the Bespoke Gene Therapy Consortium (BGTC) was launched in October 2021 to “accelerate development of gene therapies for the 30 million Americans who suffer from a rare disease.”

FDA 40

FDA Therapies Clinical Trials Disease 40

DrugBank

DECEMBER 18, 2024

This may enable the development of highly targeted therapies and individualized treatment plans, maximizing therapeutic efficacy while minimizing the risk of adverse side effects. DTx presents a unique opportunity for pharmaceutical companies to diversify their product portfolios and create new revenue streams.

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Treatment Therapies 52

The Pharma Data

JANUARY 4, 2021

The FDA has released a draft guidance on investigational new drug (IND) submissions by developers of individualized gene therapies that use antisense oligonucleotides (ASO), as part of the agency’s ongoing efforts to encourage orphan drugs.

Production 52

Production FDA Pharmaceutical Companies Drugs 52

The Pharma Data

MAY 17, 2021

Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Uharek is a hematologist and cell and gene therapy specialist at Berlin’s Charité Hospital.

Clinical Trials 52

Clinical Trials Therapies Pharmaceutical Companies International 52